Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Prozac could treat eye condition that affects half a million people, analysis suggests
Animal research by the same team of scientists who analysed the data also found that the drug - which costs £2 a pill - slows down the rate at which age-related macular degeneration progresses. (Source: the Mail online | Health)
Source: the Mail online | Health - December 7, 2021 Category: Consumer Health News Source Type: news

Predictors of Macular Degeneration Include Alcohol, Smoking Predictors of Macular Degeneration Include Alcohol, Smoking
Smoking or consuming alcohol was causally linked with an increased risk of advanced age-related macular degeneration, while smoking cessation decreased the risk of developing advanced AMD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Repurposing drugs to treat age-related macular degeneration
Researchers found that the antidepressant fluoxetine blocks the inflammation that leads to dry age-related macular degeneration, or AMD, a common cause of vision loss. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - November 9, 2021 Category: Consumer Health News Source Type: news

Study: Genetic links to smoking, alcohol use may raise eye disease risk
People genetically predisposed to developing a smoking habit who then become regular tobacco users increase their risk for age-related macular degeneration, a study published by JAMA Ophthalmology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 4, 2021 Category: Consumer Health News Source Type: news

First Implant Approved for Wet Macular Degeneration First Implant Approved for Wet Macular Degeneration
For the first time, an implant for age-related macular degeneration won approval from the FDA.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizumab, is the f...
Source: Roche Media News - October 22, 2021 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizumab, is the f...
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Susvimo (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration (AMD)
South San Francisco, CA -- October 22, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 22, 2021 Category: Drugs & Pharmacology Source Type: news

DNA in Cell Cytoplasm Implicated in Age-Related Blindness
A new study suggests that DNA synthesized in the cell cytoplasm drives retinal cell death in an advanced form of age-related macular degeneration, a leading cause of blindness. (Source: The Scientist)
Source: The Scientist - September 29, 2021 Category: Science Tags: News & Opinion Source Type: news

Millions with eye conditions at higher risk of dementia, shows research
People with macular degeneration, cataracts and diabetes-related eye disease at greater riskMillions of people with eye conditions including age-related macular degeneration, cataracts and diabetes-related eye disease have an increased risk of developing dementia, new research shows.Vision impairment can be one of the first signs of the disease, which is predicted to affect more than 130 million people worldwide by 2050.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 13, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Medical research Health Dementia Blindness and visual impairment Society Source Type: news

AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other ch... Biopharmaceuticals, Regenerative Medicine, Ophthalmology AbbVie, REGENXBIO, gene therapy, macular degeneration, diabetic retinopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 13, 2021 Category: Pharmaceuticals Source Type: news

Artificial Intelligence-Based Predictions in Neovascular AMD Artificial Intelligence-Based Predictions in Neovascular AMD
What role could artificial intelligence have in the clinical management of neovascular age-related macular degeneration?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2021 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Bayer Middle East brings Alleye home monitoring programme to Egypt
The German pharma giant is working with top eye hospitals in the country to support virtual care for patients with Diabetic Macular Edema or age-related macular degeneration. (Source: mobihealthnews)
Source: mobihealthnews - September 3, 2021 Category: Information Technology Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news